Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy. Previous reports had indicated that the lower affinity F allele affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and is linked...

Full description

Bibliographic Details
Main Authors: Heiner Zimmermann, Theresa Weiland, Jamie P. Nourse, Maher K. Gandhi, Petra Reinke, Ruth Neuhaus, Mohsen Karbasiyan, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Ralf U. Trappe, Stephan Oertel
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2014/264723

Internet

http://dx.doi.org/10.1155/2014/264723

Similar Items